The US government has been promising a crackdown on tax inversion deals for months. Yet the measures announced Monday may not be disincentive enough.» Read More
Allergan's board of directors announced on Tuesday that it has unanimously rejected a revised, unsolicited buyout offer from Valeant Pharmaceuticals.
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.
An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.
Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.
This is the perfect environment for investing in stocks, Fred Alger Management's Daniel Chung said. Here are two names he likes.
A small agricultural biotech company in Ames, Iowa, may have found a treatment for a disease that's wiping out pigs.
Clovis shares fell to a 52-week low Tuesday on concerns its cancer drug won't be able to compete with rival AstraZeneca.
Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.
Clovis Oncology CEO Patrick J. Mahaffy, talks about competing with larger companies like AstraZeneca when it comes to new cancer drugs. You compete on data, he says.
A new Clovis cancer drug has been associated with high blood sugar and linked to diabetes in trial. CEO Patrick J. Mahaffy, Clovis Oncology, weighs in on the recent report.
Valeant and ally Pershing Square prepared to take its $53.8 billion takeover bid for Allergan directly to shareholders.
Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.
As the ASCO meeting gets underway in Chicago, here's a look at where we stand in the fight against cancer.
A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?
What's next for Pfizer, now that its bid for AstraZeneca has been laid to rest, at least temporarily. Analysts weigh in with their views.
Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.
As debate rages over costly drugs like Gilead's Solvadi, patients caution: Treatment is priceless.
CNBC biotech and pharmaceutical reporter Meg Tirrell discusses what happens on the flip-side of high health-care costs—when antibiotic costs become too low and stifle development.
Get the best of CNBC in your inbox